HRP20110332T1 - TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 - Google Patents

TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 Download PDF

Info

Publication number
HRP20110332T1
HRP20110332T1 HR20110332T HRP20110332T HRP20110332T1 HR P20110332 T1 HRP20110332 T1 HR P20110332T1 HR 20110332 T HR20110332 T HR 20110332T HR P20110332 T HRP20110332 T HR P20110332T HR P20110332 T1 HRP20110332 T1 HR P20110332T1
Authority
HR
Croatia
Prior art keywords
group
branched
unbranched
atom
groups
Prior art date
Application number
HR20110332T
Other languages
English (en)
Croatian (hr)
Inventor
Sus�n Edit
Bo�r Kinga
Kapui Zolt�n
T�m�ri G�za
Btori Sndor
Szlvik Zoltn
Mikus Endre
Varg�n� Szeredi Judit
Finet Michel
Urb�n-Szab� Katalin
Szab Tibor
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20110332T1 publication Critical patent/HRP20110332T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
HR20110332T 2007-06-07 2008-06-02 TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 HRP20110332T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700395A HUP0700395A2 (en) 2007-06-07 2007-06-07 Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
PCT/HU2008/000063 WO2008149168A1 (en) 2007-06-07 2008-06-02 Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands

Publications (1)

Publication Number Publication Date
HRP20110332T1 true HRP20110332T1 (hr) 2011-06-30

Family

ID=89987565

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110332T HRP20110332T1 (hr) 2007-06-07 2008-06-02 TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3

Country Status (44)

Country Link
US (1) US8338411B2 (de)
EP (1) EP2167470B1 (de)
JP (1) JP5487100B2 (de)
KR (1) KR20100031610A (de)
CN (1) CN101679272B (de)
AR (1) AR066873A1 (de)
AT (1) ATE502016T1 (de)
AU (1) AU2008259534B2 (de)
BR (1) BRPI0812257A2 (de)
CA (1) CA2689612A1 (de)
CL (1) CL2008001648A1 (de)
CO (1) CO6270233A2 (de)
CR (1) CR11171A (de)
CY (1) CY1111644T1 (de)
DE (1) DE602008005589D1 (de)
DK (1) DK2167470T3 (de)
DO (1) DOP2009000276A (de)
EC (1) ECSP099783A (de)
ES (1) ES2363672T3 (de)
GT (1) GT200900301A (de)
HN (1) HN2009003357A (de)
HR (1) HRP20110332T1 (de)
HU (1) HUP0700395A2 (de)
IL (1) IL202471A0 (de)
JO (1) JO2689B1 (de)
MA (1) MA31738B1 (de)
ME (1) ME00958B (de)
MX (1) MX2009013209A (de)
MY (1) MY148654A (de)
NI (1) NI200900210A (de)
NZ (1) NZ581186A (de)
PA (1) PA8782901A1 (de)
PE (1) PE20090325A1 (de)
PL (1) PL2167470T3 (de)
PT (1) PT2167470E (de)
RU (1) RU2489432C2 (de)
SI (1) SI2167470T1 (de)
SV (1) SV2009003420A (de)
TN (1) TN2009000482A1 (de)
TW (1) TWI424998B (de)
UA (1) UA99463C2 (de)
UY (1) UY31130A1 (de)
WO (1) WO2008149168A1 (de)
ZA (1) ZA200908280B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010270797B2 (en) 2009-07-08 2015-03-19 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
FR3053968A1 (fr) * 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
CR20240015A (es) 2016-09-24 2024-04-05 Novo Nordisk As COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (de) 2018-05-18 2021-04-28 Incyte Corporation Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
GR76063B (de) * 1981-04-03 1984-08-03 Roussel Uclaf
ZA836701B (en) * 1982-10-01 1984-10-31 Roussel Uclaf Imidazo(1,2-a)quinolines
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EP1390349B1 (de) * 2001-05-31 2012-07-25 Sanofi Aminochinolin- und aminopyridinderivate und deren verwendung als adenosin a3 liganden
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US20050107611A1 (en) 2001-12-21 2005-05-19 Barbara Matuszczak Pyrazolyl-substituted triazoloquinoxalines
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
BRPI0412577A (pt) * 2003-07-31 2006-09-19 Sanofi Aventis derivados de aminoquinolina e seu uso como ligantes de adenosina a3

Also Published As

Publication number Publication date
ES2363672T3 (es) 2011-08-11
UA99463C2 (en) 2012-08-27
MA31738B1 (fr) 2010-10-01
ATE502016T1 (de) 2011-04-15
TN2009000482A1 (en) 2011-03-31
WO2008149168A8 (en) 2010-01-07
HU0700395D0 (en) 2007-07-30
BRPI0812257A2 (pt) 2014-12-23
CN101679272B (zh) 2013-02-06
US8338411B2 (en) 2012-12-25
TW200914451A (en) 2009-04-01
JP5487100B2 (ja) 2014-05-07
CA2689612A1 (en) 2008-12-11
ME00958B (me) 2012-06-20
JP2010529100A (ja) 2010-08-26
MY148654A (en) 2013-05-15
NZ581186A (en) 2012-03-30
PL2167470T3 (pl) 2011-08-31
EP2167470B1 (de) 2011-03-16
MX2009013209A (es) 2010-04-09
GT200900301A (es) 2010-04-22
ZA200908280B (en) 2010-07-28
HUP0700395A2 (en) 2009-03-02
JO2689B1 (en) 2013-03-03
CY1111644T1 (el) 2015-10-07
CN101679272A (zh) 2010-03-24
CO6270233A2 (es) 2011-04-20
WO2008149168A1 (en) 2008-12-11
AR066873A1 (es) 2009-09-16
CL2008001648A1 (es) 2008-10-10
HN2009003357A (es) 2013-08-12
PA8782901A1 (es) 2009-01-23
AU2008259534A1 (en) 2008-12-11
PE20090325A1 (es) 2009-04-17
TWI424998B (zh) 2014-02-01
DE602008005589D1 (de) 2011-04-28
EP2167470A1 (de) 2010-03-31
US20100216786A1 (en) 2010-08-26
SV2009003420A (es) 2010-04-26
UY31130A1 (es) 2009-01-30
KR20100031610A (ko) 2010-03-23
PT2167470E (pt) 2011-05-16
RU2489432C2 (ru) 2013-08-10
RU2009149518A (ru) 2011-07-20
SI2167470T1 (sl) 2011-06-30
IL202471A0 (en) 2010-06-30
NI200900210A (es) 2010-07-15
CR11171A (es) 2010-04-21
AU2008259534B2 (en) 2012-07-05
DK2167470T3 (da) 2011-06-27
DOP2009000276A (es) 2010-01-31
ECSP099783A (es) 2010-01-29
HK1138581A1 (en) 2010-08-27

Similar Documents

Publication Publication Date Title
HRP20110332T1 (hr) TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3
JP2009529047A5 (de)
JP5978293B2 (ja) Ｎａｍｐｔを阻害するための新規な化合物および組成物
CA3180372A1 (en) 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors
KR20010050223A (ko) Ｃｒｆ 길항제 및 관련 조성물의 용도
BR112013004773B1 (pt) Compostos, seus usos, e composições para a inibição de nampt
US9181238B2 (en) N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors
JP2011500809A (ja) 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
KR20100087291A (ko) 케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물
BRPI0610382A2 (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
JP5687617B2 (ja) 運動障害治療剤
AU2006297124A1 (en) 2-amino-7,8-dihydro-6H-pyrido(4,3-d) pyrimidin-5-ones
CN102482272A (zh) 情绪障碍治疗剂
US11793821B2 (en) Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
EP3286179A1 (de) Zusammensetzungen und verfahren zur hemmung von kinasen
AU2017262155B2 (en) Certain protein kinase inhibitors
CN108601773B (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
RS20050364A (sr) Derivati imidazokvinolina kao veznici a3 receptora adenozina
US10870630B2 (en) Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
JP5663485B2 (ja) 不安障害治療剤
JP2024516430A5 (de)
RS56104A (sr) Derivati imidazohinolina
TW202612700A (zh) 發炎性腸道疾病之治療
CN113966329B (zh) 作为pdl1检查点抑制剂的杂环免疫调节剂